期刊
MOLECULAR THERAPY-NUCLEIC ACIDS
卷 29, 期 -, 页码 955-968出版社
CELL PRESS
DOI: 10.1016/j.omtn.2022.08.033
关键词
-
资金
- Clarendon Fund
- Juel-Jenson Scholarship from St Cross College, Oxford
- MRC Programme Grant
- Medical Research Council (MRC)
This study aimed to determine whether exon skipping using a peptide-phosphorodiamidate morpholino oligonucleotide (PPMO) conjugate results in dose-dependent restoration of uniform dystrophin localization in DMD patients. The results demonstrated that PPMO-mediated exon skipping generates myofibers with uniform dystrophin expression and restores serum microRNA biomarkers and muscle stiffness in a dose-dependent manner. These findings suggest the potential utility of PPMO as a therapeutic approach for restoring dystrophin in DMD.
Therapies that restore dystrophin expression are presumed to correct Duchenne muscular dystrophy (DMD), with anti -sense-mediated exon skipping being the leading approach. Here we aimed to determine whether exon skipping using a peptide-phosphorodiamidate morpholino oligonucleotide (PPMO) conjugate results in dose-dependent restoration of uniform dystrophin localization, together with correction of putative DMD serum and muscle biomarkers. Dystrophin-deficient mdx mice were treated with a PPMO (Pip9b2-PMO) designed to induce Dmd exon 23 skipping at single, ascending intravenous doses (3, 6, or 12 mg/kg) and sacrificed 2 weeks later. Dose-dependent exon skipping and dystrophin protein restoration were observed, with dystrophin uniformly distributed at the sarcolemma of corrected myofibers at all doses. Serum microRNA biomarkers (i.e., miR-1a-3p, miR-133a-3p, miR-206-3p, miR-483-3p) and creatinine kinase levels were restored toward wild-type levels after treatment in a dose -dependent manner. All biomarkers were strongly anti -correlated with both exon skipping level and dystrophin expression. Dystrophin rescue was also strongly positively correlated with muscle stiffness (i.e., Young's modulus) as determined by atomic force microscopy (AFM) nanoindentation assay. These data demonstrate that PPMO-mediated exon skipping generates myofibers with uniform dystrophin expression and that both serum microRNA biomarkers and muscle AFM have potential utility as pharmacodynamic biomarkers of dystrophin restoration therapy in DMD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据